Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Sensyne Health on IPO and Pioneering Strategic Agreements

August 17, 2018

LONDONCovington has advised Sensyne Health on medical device regulatory and data protection matters in connection with its £60 million IPO on London’s AIM market. The firm also represented Sensyne Health in negotiating strategic research and data processing agreements with the Chelsea and Westminster Hospital NHS Foundation Trust, the Oxford University Hospitals NHS Foundation Trust, and the South Warwickshire NHS Foundation Trust.

Following admission, Sensyne Health will have a market capitalization of approximately £225 million. Sensyne Health creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis and commercialisation of real-world evidence from large databases of anonymised patient data in collaboration with its NHS Trust partners. Financial returns generated by Sensyne Health are shared with its NHS Trust partners via equity ownership in Sensyne Health and a share of royalties.

The Covington team included Daniel Pavin and Joshua Gray (Technology Transactions/Data Protection), Grant Castle and Sarah Cowlishaw (Life Sciences Regulatory), and Simon Amies (Corporate).  

Sensyne Health was also advised by law firms Allen & Overy and Osborne Clarke.

Share this article: